The presence of TP53 gene variants in MDS is associated with high-risk disease progression with rapid transformation to AML, independently of the revised International Prognostic Scoring System (IPSS-R), resistance to treatment, and dismal outcomes [10,74,75]. The gene discussed is TP53; the disease is acute myeloid leukemia.